Dyax buys rights to angiogenesis technology:
This article was originally published in Clinica
Biopharmaceutical company Dyax has bought exclusive rights to develop diagnostic products and antibody drugs for an undisclosed angiogenesis target from Licentia. Helsinki, Finland-based Licentia focuses on licensing and commercialising scientific research results. Its shareholders include the University of Helsinki and the Helsinki University of Technology. Dyax has also formed a research collaboration with Dr Kari Alitalo from the University of Helsinki.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.